Clarisse Lobo, Aderson Araújo, Alexandre de Albuquerque Antunes, Ana Cristina Silva Pinto, Ariadne Carvalho Godinho, Cassia Silvestre Mariano Pires, Cinthia Cristina Matheus, Xerez de Albuquerque, Daniele Campos Fontes Neves, Fábio de Lima Moreno, Giorgio Baldanzi, Grazziella Curado Siufi, Heloisa Helena Pereira Miranda, Jane Hankins, Joice Aragão, Josefina Aparecida Pellegrini Braga, Juliana Touguinha Neves Martins, Luciana Campos Costa Machado de Souza, Maria Stella Figueiredo, Mirella Rodrigues Oliveira, Patricia Santos Resende Cardoso, Patricia Costa Alves Pinto, Patricia Gomes Moura, Rodolfo Delfino Cançado, Paulo Ivo Cortez de Araujo, Sara Olalla Saad, Sandra Regina Loggetto, Teresa Cristina Cardoso Fonseca
To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea...
February 1, 2024: Hematology, Transfusion and Cell Therapy